Australia's most trusted
source of pharma news
Monday, 07 October 2024
Posted 26 September 2024 PM
London-based start-up Vicebio has raised US$100 million in Series B financing to continue developing the molecular clamp platform against life-threatening respiratory viral infections.
ViceBio, led by former GSK exec Emmanuel Hannon, was established in 2019 by investment firm Medicxi to develop novel vaccines using the University of Queensland's tech, which made headlines early in the Covid vaccine race.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.